Utility of positron emission tomography for drug development for heart failure

Lampros Papadimitriou, Peter M. Smith-Jones, Chaudhry M.S. Sarwar, Catherine N. Marti, Kavitha Yaddanapudi, Hal A. Skopicki, Mihai Gheorghiade, Ramin Parsey, Javed Butler*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Only about 1 in 5,000 investigational agents in a preclinical stage acquires Food and Drug Administration approval. Among many reasons for this includes an inefficient transition from preclinical to clinical phases, which exponentially increase the cost and the delays the process of drug development. Positron emission tomography (PET) is a nuclear imaging technique that has been used for the diagnosis, risk stratification, and guidance of therapy. However, lately with the advance of radiochemistry and of molecular imaging technology, it became evident that PET could help novel drug development process. By using a PET radioligand to report on receptor occupancy during novel agent therapy, it may help assess the effectiveness, efficacy, and safety of such a new medication in an early preclinical stage and help design successful clinical trials even at a later phase. In this article, we explore the potential implications of PET in the development of new heart failure therapies and review PET's application in the respective pathophysiologic pathways such as myocardial perfusion, metabolism, innervation, inflammation, apoptosis, and cardiac remodeling.

Original languageEnglish (US)
Pages (from-to)142-152
Number of pages11
JournalAmerican heart journal
StatePublished - May 1 2016

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Utility of positron emission tomography for drug development for heart failure'. Together they form a unique fingerprint.

Cite this